Novartis (NVS) reported Q3 EPS of $1.58, $0.02 better than the analyst estimate of $1.56. Revenue for the quarter came in at $12.54 billion versus the consensus estimate of $12.92 billion.
GUIDANCE:
2022 Group guidance confirmed at mid single digit sales and core operating income growth. Sandoz guidance revised upwards, with sales expected to grow low to mid single digit (from low single digit) and core operating income expected to grow low single digit (from broadly in line).